

PreSate...

Chlorphentermine HCl

DESCRIPTION: PRE-SATE (Chlorphentermine HCl) is an effective appetite suppressant with a pattern of pharmacologic action substantially different from those of traditional anorexigenics. In providing dependable appetite control with appreciable loss of body weight, PRE-SATE does not significantly increase central nervous system (CNS), cardiorespiratory or metabolic activity.

COMPOSITION: Each tablet contains 65 mg of chlorphentermine (p-chloro-1, 1-dimethylphenethylamine) as the hydrochloride, and has been formulated to begin producing its effects one hour after ingestion. When taken with or shortly after the first meal of the day these effects continue throughout most patients' normal range of waking hours.

ACTION: Evidence indicates that food intake is at least partially regulated by the functional association of two sites in the hypothalamus, i.e. the satiety centre and the feeding centre. Stimulation of the satiety centre produces impulses which inhibit the activity of the feeding centre and cause eating to stop. Results of tests conducted in animals indicate that PRE-SATE blocks the actual eating of food, but does not affect impulses that motivate the search for food. Additionally, tests have shown that PRE-SATE changed the pattern of impulses in the feeding and satiety centres of starved animals to a pattern indicating that the animals were well fed. These findings in animals have been interpreted as an indication that the effect of PRE-SATE on the regulation of food intake is mediated through the satiety centre.

INDICATIONS: PRE-SATE is indicated as an adjunct in the short term (i.e. a few weeks) management of exogenous obesity and related less serious overweight conditions in conjunction with a medically supervised regimen of weight reduction based on caloric restriction.

CONTRAINDICATIONS: Patients who have glaucoma, thyrotoxicosis or in patients who are receiving MAO inhibitors.

PRECAUTIONS: Use with caution in patients with hypertensive and other cardiovascular disease and hyperthyroidism. Safety in human pregnancy is not yet established. Use in lactating women is not recommended.

ADVERSE EFFECTS: Mydriasis, nausea, constipation, dry mouth and, rarely, difficulty in initiating micturition. Nervousness and insomnia, as well as drowsiness, and sedation have been reported. Also, headache, excessive perspiration, rash, diarrhea, urticaria and dizziness.

DOSAGE: Adults: 65 mg (one tablet) taken with or shortly after the first meal of the day. Tablets should be swallowed whole.

SUPPLIED: Each blue-grey tablet, monogrammed W/C, contains 65 mg of chlorphentermine base as the hydrochloride. Available in bottles of 30 and 250 tablets.

Warner/Chilcott

Laboratories Co. Limited,
Toronto, Canada

1 NEW PRODUCTS

X-ray System Said To Reduce Radiation Exposure

THE 3M Trimax Micro Dosage Imaging System is a new X-ray system which claims an eight-fold reduction in patient's exposure to radiation over conventional X-ray methods.

The Trimax system consists only of rare earth phosphor intensifying screens and 3M X-ray film. The new system is compatible with current processing chemistry and X-ray facilities. According to the manufacturers, this system matches conventional medium speed systems in quality of X-ray, but reduces radiation exposure to the patient because of the rare earth phosphors' efficiency in converting ionizing radiation to light.

The manufacturers also claim a number of advantages to the new system, in addition to reduced radiation exposure to patients. They say that high speeds will permit the shooting of detailed X-rays at higher levels of magnification, possibly leading to earlier detection of kidney, brain, lung and heart disease.

Another advantage, say the manufacturers, is that the shorter exposure time 'freezes' the patient's motion. Involuntary movements in children, the unconscious and elderly patients become less of a problem, thus reducing the number of retakes and ultimately, radiation exposure and cost. With lower radiation requirements, the manufacturers claim X-ray tubes could last eight times longer than previously, and new high powered X-ray equipment won't be necessary — the old low powered generators will suffice.

Finally, the manufacturers claim that the Trimax system will give the portable X-ray machine in the operating room fast results, equivalent to those in the X-ray department.

For further information contact: 3M Canada Ltd., P.O. Box 5757, London, Ont. N5A 4T1.

YOMESAN — (niclosamide) is manufactured as a treatment for tapeworm infestation, including beef, pork, fish and dwarf tapeworm. The manufacturers say that the vermifugal action of the drug renders the tapeworm, especially its head and proximal segments, vulnerable to the digestive juices, which can then destroy them during their passage through the gut. The product is available in individual packages of 4 x 500 mg tablets.

For further information contact: Boehringer Ingelheim (Canada) Ltd., 2121 TransCanada Highway, Dorval, Que. H9P 1J3.

AMOXIL — is a broad spectrum penicillin designed for treatment of ear, nose, throat, skin and soft tissue infections of the upper respiratory and genitourinary tract. The manufacturers claim the product achieves high levels regardless of the presence of food and add that 500 mg amoxil given orally achieves blood levels approximately equivalent to 500 mg ampicillin, given intramuscularly. The product is available in capsules of 250 mg and in suspension form of 125 mg and 250 mg.

For further information contact: Ayerst Laboratories, 1025 Laurentian Blvd., Saint-Laurent, Que.

Statements made in this section of CANADIAN FAMILY PHYSICIAN are taken from material provided by the manufacturers or distributors concerned, and imply no endorsement of the products. Readers interested in any of the items should contact the companies concerned.
